Combining cetuximab with oral drugs improves lung cancer response with mutated KRAS

The combined use of these treatments slows the rapid appearance of resistance of tumor cells against these oral drugs. In addition, an indicator of the appearance of these resistances, fumarate, has been identified, which could serve as a biomarker prognostic of the aggressiveness of these tumors.This work, entitled Cetuximab, enhances the cytotoxicity of fulzerasib ysotorasib in lung cancer with KRAS mutation, whose first signatory is the bioch…